IBIO · iBio Inc. Common Stock
View on chartInsiders & Stakes
| Maddux Randy Joe Chief Operating Officer | ▼ Sell | Open Market | 271,757 Shares held | 12/7/2021 | View profile |
| Antonio Bernardino Guimaraes Parada Director | ▲ Buy | Open Market | 183,823 Shares held | 1/10/2025 | View profile |
| Robert Matthew Lutz Chief Operating Officer | ▲ Buy | Grant | 102,165 Shares held | 11/11/2022 | View profile |
| Felipe Duran Chief Financial Officer | ▲ Buy | Open Market | 35,974 Shares held | 3/19/2026 | View profile |
| Martin Brenner Chief Scientific Officer | ▲ Buy | Open Market | 30,652 Shares held | 3/19/2026 | View profile |
| Marc Banjak Chief Legal Officer | ▲ Buy | Open Market | 25,000 Shares held | 3/26/2026 | View profile |
| David Arkowitz Director | ▲ Buy | Open Market | 18,382 Shares held | 1/10/2025 | View profile |
| Gary Sender Director | ▲ Buy | Open Market | 9,191 Shares held | 1/10/2025 | View profile |
| William D. Clark Director | ▲ Buy | Open Market | 1,838 Shares held | 1/10/2025 | View profile |
Transaction History
| Marc Banjak | ▲ Buy | Open Market | 12,500 | $21K | 3/26/2026 |
| Marc Banjak | ▲ Buy | Open Market | 1,434 | $3K | 3/26/2026 |
| Martin Brenner | ▲ Buy | Open Market | 12,336 | $25K | 3/19/2026 |
| Felipe Duran | ▲ Buy | Open Market | 24,835 | $50K | 3/19/2026 |
| Felipe Duran | ▲ Buy | Open Market | 9,191 | $25K | 1/10/2025 |
| Martin Brenner | ▲ Buy | Open Market | 9,191 | $25K | 1/10/2025 |
| Marc Banjak | ▲ Buy | Open Market | 9,191 | $25K | 1/10/2025 |
| David Arkowitz | ▲ Buy | Open Market | 18,382 | $50K | 1/10/2025 |
| William D. Clark | ▲ Buy | Open Market | 1,838 | $5K | 1/10/2025 |
| Antonio Bernardino Guimaraes Parada | ▲ Buy | Open Market | 183,823 | $500K | 1/10/2025 |
| Gary Sender | ▲ Buy | Open Market | 9,191 | $25K | 1/10/2025 |
| Martin Brenner | ▼ Sell | Open Market | 4,881 | $1K | 11/1/2023 |
| Martin Brenner | ▼ Sell | Open Market | 5,267 | $2K | 10/3/2023 |
| Martin Brenner | ▼ Sell | Open Market | 4,215 | $1K | 10/2/2023 |
| Martin Brenner | ▼ Sell | Open Market | 5,011 | $2K | 8/28/2023 |
| Martin Brenner | ▼ Sell | Open Market | 4,480 | $2K | 7/27/2023 |
| Martin Brenner | ▼ Sell | Open Market | 35 | $18 | 7/27/2023 |
| Martin Brenner | ▼ Sell | Open Market | 47,020 | $28K | 7/12/2023 |
| Martin Brenner | ▲ Buy | Grant | 75,833 | $0 | 6/26/2023 |
| Martin Brenner | ▼ Sell | Other | 75,833 | $0 | 6/22/2023 |
| Martin Brenner | ▼ Sell | Open Market | 3,859 | $3K | 6/21/2023 |
| Martin Brenner | ▼ Sell | Open Market | 225 | $155 | 6/21/2023 |
| Martin Brenner | ▼ Sell | Open Market | 100 | $68 | 6/21/2023 |
| Martin Brenner | ▼ Sell | Open Market | 4,158 | $4K | 5/22/2023 |
| Martin Brenner | ▼ Sell | Open Market | 24 | $23 | 5/22/2023 |
| Martin Brenner | ▼ Sell | Open Market | 4,382 | $5K | 4/24/2023 |
| Martin Brenner | ▲ Buy | Grant | 50,000 | $0 | 3/31/2023 |
| Felipe Duran | ▲ Buy | Grant | 37,500 | $0 | 3/31/2023 |
| Martin Brenner | ▼ Sell | Open Market | 5,213 | $11K | 3/23/2023 |
| Martin Brenner | ▼ Sell | Open Market | 3,976 | $7K | 2/21/2023 |
| Martin Brenner | ▲ Buy | Grant | 130,000 | $0 | 1/20/2023 |
| Martin Brenner | ▲ Buy | Grant | 95,348 | $0 | 11/11/2022 |
| Robert Matthew Lutz | ▲ Buy | Grant | 100,057 | $0 | 11/11/2022 |
| Robert Matthew Lutz | ▼ Sell | Open Market | 24,625 | $9K | 3/10/2022 |
| Maddux Randy Joe | ▼ Sell | Open Market | 37,243 | $25K | 12/7/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
iBio to Present Data at 2026 EASD Annual Meeting
iBio Inc. announced it will present at the 2026 EASD Annual Meeting. This event is relevant as it provides a platform to share updates on the company's medical technology. The stock is currently trading near its 52-week low, with an RSI of 24.6 indicating oversold conditions. Analysts maintain an average price target of $5.69, significantly above the current market price.
iBio to Present Data at 2026 EASD Annual Meeting. iBio Inc. announced it will present at the 2026 EASD Annual Meeting. This event is relevant as it provides a platform to share updates on the company's medical technology. The stock is currently trading near its 52-week low, with an RSI of 24.6 indicating oversold conditions. Analysts maintain an average price target of $5.69, significantly above the current market price.